You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: FasCure Therapeutics LLC Topic: 102
DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: QRKANSWER LLC Topic: NCI
DESCRIPTION provided by applicant Cancer is a major public health problem and a leading cause of mortality claiming more than half million lives every year in the US While major progresses have been made in developing targeted anticancer therapeutics many cancers such as lung cancers have no effective treatments Unfortunately many ideal oncogenic targets including transcription factors for ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Medosome Biotec, LLC Topic: NIAID
DESCRIPTION provided by applicant Adeno associated virus AAV is a non pathogenic human parvovirus and recombinant AAV vectors have gained significant attention owing to their safety and in some cases clinical efficacy in a number of Phase I II clinical trials However relatively large vector doses are needed to achieve clinical efficacy and such high doses can lead to host immune respon ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: FreezeBack, LLC Topic: OD
DESCRIPTION provided by applicant Freezing whole zebrafish embryos in order to later recover live fish is not currently possible Researchers seeking to preserve zebrafish genetic lines are presently limited to the options of storing frozen sperm in sperm banks or maintaining the fish alive These limitations increase costs and hinder the efficient dissemination of superior wild type and mutan ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Medosome Biotec, LLC Topic: NIAID
DESCRIPTION provided by applicant Drug resistance to HIV is a major threat to achieving long term viral suppression in HIV individuals Up to of newly infected individuals acquire HIV with resistance to at least one of the major antiretroviral classes and incomplete viral suppression and virologic failure are often associated with drug resistance Therefore current DHHS guideline recomme ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Medosome Biotec, LLC Topic: NIAMS
DESCRIPTION provided by applicant The pursuit of novel therapies informed by the astounding advances in biomedical science of the past half century has been fruitful for many disorders However inherited muscle diseases such as muscular dystrophy remain stubbornly resistant to sophisticated molecular approaches to therapy A few therapies are finally edging towards approval but it has become ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: CoPlex Therapeutics, LLC Topic: NIA
ABSTRACT Traditional approaches to drug development for Alzheimer s disease are becoming increasingly expensive and in many cases disappointingly unsuccessful Based on preliminary in vitro and in vivo studies we have identified a novel small molecule methyl dimethyl oxo dihydrobenzo c naphthyridine carboxylate UK that significantly decreases A production and pro in ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Vibronix, Inc. Topic: O
After a breast conserving therapy histology is often performed to check whether the excised tumor specimen is surrounded by a sufficient amount of normal tissue If a positive margin is identified then a second operation will be performed Currently the re operation rate is which raises a need for intraoperative detection of residual cancers The current intraoperative tools for margin ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Medosome Biotec, LLC Topic: NICHD
ABSTRACT SUMMARY Pyruvate dehydrogenase complex PDC deficiency PDCD is a rare disease of mitochondrial energy failure in which the life of expectancy of affected children is severely truncated Treatment of PDCD remains a serious unmet challenge There has never been a controlled trial of any intervention for PDCD thus there is no proven therapy for affected patients Dichloroacetate DCA ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
Fully Metallic Self-Fragmenting Structural Reactive Materials Using Composites and Alloys Comprised of Aluminum, Lithium, and MagnesiumSBC: Adranos Energetics LLC Topic: DTRA16A002
While aluminum casing materials provide some enhanced performance and thermal loading to explosive ordinance, their overall effectiveness is highly limited by incomplete combustion and long residence times. In order to reduce these problems, the casing material must be designed to facilitate rapid fragmentation through either specialized casing geometries or greatly refined initial particle sizes. ...STTR Phase I 2016 Department of DefenseDefense Threat Reduction Agency